Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study
Author:
Joseph Biederman,Suma Krishnan,Yuxin Zhang,James J. McGough,Robert L. Findling
Publication:
Clinical Therapeutics
Copyright © 2007 Published by Elsevier Inc.